Na+/k+-atpase Inhibition
Na+/k+-atpase Inhibition - Related Videos
07:38
Measuring In Vitro ATPase Activity for Enzymatic Characterization
0 Views •
Cited by 27 •
2016
We describe a basic protocol for quantitating in vitro ATPase activity. This protocol can be optimized based on the level of activity and requirements for a given purified ATPase.
00:46
Feedback Inhibition
0 Views •
2019
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell! Since enzymes help control the rate of reactions, their activity is regulated so that appropriate amounts of starting materials, intermediate metabolites, and products are maintained in the cell. Excessive build-up or depletion of...
01:30
Enzyme Inhibition
0 Views •
2025
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure. Competitive inhibitors occupy the active site of enzymes, making them unable to accommodate the substrate. However, sufficiently high...
02:29
Measuring Immune-Induced Inhibition of Seedling Growth
0 Views •
2025
This video demonstrates the seedling growth inhibition assay in the Arabidopsis thaliana plant. The impact of increased concentration of immune peptide elicitor on seedling growth is determined.
08:44
Isolation of F1-ATPase from the Parasitic Protist Trypanosoma brucei
0 Views •
Cited by 1 •
2019
This protocol describes the purification of F1-ATPase from the cultured insect stage of Trypanosoma brucei. The procedure yields a highly pure, homogeneous, and active complex suitable for structural and enzymatic studies.
FAQs
The extracellular location of cardiac glycoside binding is important because it directly limits access to the pump’s transport cycle from outside the cell. This prevents normal sodium export and potassium uptake, disrupting the gradients that support related ion movements. The binding site therefore links drug interaction at the membrane surface to downstream effects in cardiomyocytes.
Reduced sodium extrusion raises intracellular sodium in cardiomyocytes. That change reduces sodium-calcium exchange, so less calcium is moved through this linked transport process. The resulting increase in intracellular calcium strengthens contraction. This ion-coupling mechanism explains why pump inhibition can produce a positive contractile effect rather than acting only as a general disturbance of membrane transport.
The same pathway that can enhance contractility also creates risk when inhibition becomes excessive. Larger disturbances in sodium and potassium handling can produce electrolyte abnormalities and interfere with normal cardiac electrical activity, leading to arrhythmias. This narrow relationship between desired pharmacological action and harmful effects makes the degree of pump inhibition central to safety.
A therapeutic effect reflects sufficient pump inhibition to alter intracellular sodium and calcium handling in a way that increases cardiomyocyte contractility. An adverse effect reflects a greater disruption of ion balance, with electrolyte disturbances and arrhythmias. The distinction is therefore not a completely different mechanism, but the physiological consequence of the extent of pathway interference.
Digoxin provides a clinically relevant example of how cardiac glycoside action can translate into therapeutic benefit. Its relationship to Na+/K+-ATPase inhibition helps pharmacologists connect membrane transport, sodium-calcium exchange, and increased contractility with use in selected cardiac conditions. The same model also supports evaluation of toxicity, particularly when ion disturbances and arrhythmias emerge.
Evaluation should connect pump inhibition with changes in intracellular sodium, sodium-calcium exchange, contractility, electrolyte balance, and cardiac rhythm. These outcomes span the pathway from molecular drug action to cellular function and safety. Examining them together helps distinguish a useful increase in contractility from broader physiological disruption caused by excessive inhibition.